Navigation Links
Regeneron Reports First Quarter 2011 Financial and Operating Results
Date:5/3/2011

TARRYTOWN, N.Y., May 3, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2011 and provided an update on development programs and upcoming milestones.  

Clinical Programs UpdateVEGF Trap-Eye (aflibercept ophthalmic solution)– Ophthalmologic DiseasesVEGF Trap-Eye is a fusion protein locally administered in the eye that is designed to bind Vascular Endothelial Growth Factor-A (VEGF-A) and Placental Growth Factor (PlGF), proteins that are involved in the abnormal growth of new blood vessels.  Regeneron maintains exclusive rights to VEGF Trap-Eye in the United States.  Bayer HealthCare LLC has rights to market VEGF Trap-Eye outside the U.S., where the companies will share equally in profits from any future sales of VEGF Trap-Eye.

In February 2011, Regeneron submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).  In April 2011, the FDA accepted the BLA for filing and granted the Company's request for Priority Review.  Under Priority Review, the target date for an FDA decision on the VEGF Trap-Eye BLA is August 20, 2011.

Also in February 2011, data from the Phase 3 VIEW 1 and VIEW 2 trials of VEGF Trap-Eye in patients with wet AMD and the Phase 3 COPERNICUS trial in macular edema due to central retinal vein occlusion (CRVO) were presented at the Bascom Palmer Eye Institute's Angiogenesis, Exudation and Degeneration 2011 meeting. Results of the Phase 2 DA VINCI trial of VEGF Trap-Eye in diabetic macular edema (DME) were also presented.

In April 2011, Regeneron and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye in the Phase 3 GALILEO study in patients with macular edema due to CRVO.
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
2. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
3. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
4. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
5. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
6. Regeneron Announces March 2011 Investor Conference Presentations
7. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
8. Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
9. Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
10. Regeneron Announces Presentation at the ISI Annual Conference
11. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that Steven ... and David Haen , Vice President of ... corporate overview at two significant investment conferences in ... industries: the FBR & Co. Second Annual Health ...
(Date:9/1/2015)... 1, 2015 Pressure BioSciences, Inc. (OTCQB: ... the development and sale of broadly enabling, pressure ... worldwide life sciences industry, today announced the publication ... Company,s PCT Platform could play a significant role ... role is based on PCT,s unique ability to ...
(Date:9/1/2015)... , September 1, 2015 ... company, today announces that it has appointed Hilde ... Non-Executive Directors to its Board of Directors, effective immediately. ... years of experience in pharma and biotech and is ... a Sanofi company. Previously her role was Vice President ...
Breaking Medicine Technology:CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 2CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 3CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 3New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 5BerGenBio Appoints Non-Executive Directors 2
... Pricing of $500 Million of Senior Notes in Connection with... -- ARDEE, Ireland, Sept. 24 ... ... lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... Misonix, Inc. (Nasdaq: MSON ), a ... technology, which worldwide is used for acute health conditions, ... ended June 30, 2010 financial results on Tuesday, September ... Officer and Richard Zaremba, Senior VP and Chief Financial ...
Cached Medicine Technology:Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 2Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 3Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 4Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 5Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 6Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 7Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex® 8Misonix Schedules Fourth Quarter and Fiscal 2010 Financial Results Conference Call; September 28, 2010 at 4:30 p.m. Eastern 2
(Date:9/1/2015)... ... ... The FSH Society , the Massachusetts-based charity that has transformed the ... beneficiary of a collection of fundraising events this fall. From Boston to Los Angeles, ... and further FSHD research. , The list of 2015 fall events include: ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... Qualification of Laboratory Instruments in accordance with GMP requirements“ , featuring Ed Szczesny ... October 6th, 2015 at 11:00 EDT (15:00 GMT). , Calibration, qualification, and ...
(Date:9/1/2015)... NY (PRWEB) , ... September 01, 2015 , ... ... to date, more than 1,500 investor-families have received permanent green cards (I-829 petition ... projects. , The I-829 petition is the final step of the EB-5 visa ...
(Date:9/1/2015)... Aventura, Florida (PRWEB) , ... September 01, 2015 ... ... across language barriers and international borders seldom arise at the most convenient time ... which is always ready to help. , Universal Translation Services has ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... it has established the MAP Recovery Network, the Premier Outcomes-Driven Provider Network. ... This rapidly-growing alliance is dedicated to the provision of quality addiction treatment ...
Breaking Medicine News(10 mins):Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 2Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 3Health News:MAP Health Management Launches the MAP Recovery Network 2
... from International Agency for Cancer Research scientists (IACR) have ... incidence of lung cancer. ,The study was conducted ... individuals from Poland, Slovakia, Czech Republic, Romania, Russia and ... the diet. The study has found that eating cabbage ...
... Bilaspur, M. P. in its specialty hospital has a ... Bangalore based company called Televital. Now the Bilaspur Hospital ... and Nagpur. The Telemedicine network is implemented on Optical ... Indian Railway has had an optical fibre network in ...
... childbearing, and a small number of carefully planned// pregnancies, ... disappointment and grief when they occur. A study has ... whether abortion increased a woman’s chance of suffering from ... women who aborted or delivered an unwanted pregnancy reveal ...
... smoking has been widely recognized. Passive smoking has been ... with an increased risk of coronary heart disease eventually ... marker of in vivo oxidation injury, have been shown ... for passive smoking are lacking. , ,Recently, researchers ...
... starts three-year lifestyle campaign to fight osteoporosis Exercise can help ... report explains. , ,'One of the best ways to ... Helmut Minne, IOF Board member and author of Move it ... strong bones, prevent falls and fractures and speed rehabilitation. ...
... to create strange type of histories all the time. Now ... produce a baby boy after one of them was left ... an environmental assistant from Woolwich in southeast London was declared ... egg) and their eldest sister carried the fetus in ...
Cached Medicine News:Health News:Cabbage And Genes May Protect Against Lung Cancer 2Health News:Abortion Does Not Increase Risk Of Depression In Women 2Health News:Passive Cigarette Smoking Increases Isoprostane Formation 2Health News:Want Strong Bones: Exercise And Eat Right! 2
Inquire...
Calss II Type B2 Biological Safety Cabinet...
External Calibration Only. Built-in RS232 Interface, Shimadzu WindowsDirect communication function. 120/240V A/C adapter....
... Semi-Micro balance. Built-in, motor-driven internal ... Performs Fully Automatic Self-Calibration when temperature ... intervals. Menu-selected weighing parameters, plug-in ... function keypads make this balance series ...
Medicine Products: